Neil E. Stahl - 14 May 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Research and Development
Signature
/s/**Neil Stahl
Issuer symbol
REGN
Transactions as of
14 May 2021
Net transactions value
-$19,359,184
Form type
4
Filing time
18 May 2021, 16:04:14 UTC
Next filing
06 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Gift $0 -435 -1.8% $0.000000 24,280 25 Feb 2021 Direct
transaction REGN Common Stock Options Exercise $7,165,200 +40,000 +165% $179.13 64,280 14 May 2021 Direct
transaction REGN Common Stock Tax liability $14,351,065 -27,775 -43% $516.69 36,505 14 May 2021 Direct
transaction REGN Common Stock Options Exercise $650,375 +12,500 +34% $52.03 49,005 14 May 2021 Direct
transaction REGN Common Stock Tax liability $3,722,235 -7,204 -15% $516.69 41,801 14 May 2021 Direct
transaction REGN Common Stock Sale $1,752,451 -3,379 -8.1% $518.63 38,422 17 May 2021 Direct F1
transaction REGN Common Stock Sale $5,369,242 -10,336 -27% $519.47 28,086 17 May 2021 Direct F2
transaction REGN Common Stock Sale $1,979,767 -3,806 -14% $520.17 24,280 17 May 2021 Direct F3
holding REGN Common Stock 5,787 14 May 2021 By 401(k) Plan
holding REGN Common Stock 9,134 14 May 2021 by 2019 GRAT

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -12,500 -100% $0.000000* 0 14 May 2021 Common Stock 12,500 $52.03 Direct F4
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -40,000 -36% $0.000000 72,500 14 May 2021 Common Stock 40,000 $179.13 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents volume-weighted average price of sales of 3,379 shares of Company stock on May 17, 2021 at prices ranging from $518.02 to $518.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2021 at each separate price.
F2 Represents volume-weighted average price of sales of 10,336 shares of Company stock on May 17, 2021 at prices ranging from $519.00 to $519.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2021 at each separate price.
F3 Represents volume-weighted average price of sales of 3,806 shares of Company stock on May 17, 2021 at prices ranging from $520.02 to $520.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2021 at each separate price.
F4 The option became exercisable on December 31, 2014, based upon the satisfaction by the Company of certain performance criteria during the period ended December 31, 2014.
F5 The stock option award vested in four equal annual installments, commencing one year after the date of grant.